Pharmaceutical major Sun Pharma's healthy Q2 backed by its industry-beating performance in the domestic market and stellar global specialty sales have impressed brokerages across the board, prompting some of them to raise their target prices for the stock. Brokerages like Nuvama Institutional Equities and Citi have raised their price targets for Sun Pharma post its Q2 results.